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ABSTRACT 
Objective: To predict risk for non-fatal cardiovascular disease (CVD) and disease-specific 
mortality using CRF algorithms that do not involve exercise testing. 
Background: Cardiorespiratory fitness (CRF) is not routinely measured, as it requires trained 
personnel and specialized equipment.  
Methods: Participants were 43,356 adults (21% women) from the Aerobics Center Longitudinal 
Study followed between 1974 and 2003. Estimated CRF was based on sex, age, body mass 
index, waist circumference, resting heart rate, physical activity level and smoking status. Actual 
CRF was measured by a maximal treadmill test. 
Results: During a median follow-up of 14.5 years, 1,934 deaths occurred, 627 due to CVD. In a 
sub-sample of 18,095 participants, 1,049 cases of non-fatal CVD events were ascertained. After 
adjusting for potential confounders, both measured CRF and estimated CRF were inversely 
associated with risk of all-cause mortality, CVD mortality and non-fatal CVD incidence in men, 
and with all-cause mortality and non-fatal CVD in women. The risk reduction per 1-metabolic 
equivalent (MET) increase ranged approximately from 10 to 20 %. Measured CRF had a slightly 
better discriminative ability (c-statistic) than estimated CRF, and the net reclassification 
improvement (NRI) of measured CRF vs. estimated CRF was 12.3% in men (p<0.05) and 19.8% 
in women (p<0.001). 
Conclusions: These algorithms utilize information routinely collected to obtain an estimate of 
CRF that provides a valid indication of health status. In addition to identifying people at risk, this 
method can provide more appropriate exercise recommendations that reflect initial CRF levels. 
 
KEY WORDS: cardiorespiratory fitness, mortality, cardiovascular disease, algorithms 
 
ABBREVIATIONS LIST 
 
ACLS = Aerobics Center Longitudinal Study. 
BMI = body mass index. 
CRF = cardiorespiratory fitness. 
CVD = cardiovascular disease. 
MET = metabolic equivalent. 
NRI = net reclassification improvement. 
RHR = resting heart rate. 
VO2max = maximal oxygen uptake. 
WC = waist circumference. 
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INTRODUCTION 
Low cardiorespiratory fitness (CRF) is associated with increased risk of cardiovascular 
disease (CVD), type 2 diabetes, and all-cause and disease-specific mortality (1-4). The most 
valid measure of CRF is cardiopulmonary exercise testing (CPX) with maximal oxygen uptake 
(VO2max) measured by ventilatory expired gas analysis (5). The common approach, however, is 
to calculate VO2max from total test time, which has demonstrated to be highly valid and easier to 
use widely (6,7). In a healthy 40 year-old, 70 kg man, 1 metabolic equivalent (MET) unit is 
defined as 3.5 mL O2 ·  kg-1 ·  min-1 (8), and every 1-MET increase has been associated with a 
13% and 15% risk reduction of all-cause mortality and CVD events, respectively (9). 
Unlike other important risk factors, CRF is not routinely measured. It requires trained 
personnel to administer an exercise test using specialized equipment. With the publication of 
non-exercise algorithms, it is now feasible to estimate CRF with reasonable accuracy using 
health indicators typically available in field and healthcare settings. Over two decades ago, we 
published the first equations (10) and many others have been developed more recently (11-15). 
Although they provide accurate estimates at the population level, these models were developed 
with cross-sectional data. Furthermore, age was included as a linear term and recent longitudinal 
data demonstrated that CRF declines nonlinearly with aging (16). To address this issue, we 
recently developed new longitudinal algorithms that estimate CRF changes associated with aging 
(17). The error estimates ranged from 1.41 to 1.69 METs (17). 
Whether estimated CRF can predict health risk is yet to be determined. To the best of our 
knowledge, only Stamatakis et al. (18) have explored the association between estimated CRF and 
mortality. After a mean follow-up of 9 years, a higher level of estimated CRF was associated 
with a lower risk of mortality from all causes and CVD (18). Interestingly, estimated CRF had a 
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better discriminative ability (as judged by c-statistic) than any of its modifiable components 
(body mass index [BMI], self-reported physical activity, and resting heart rate [RHR]) (18). 
Given the underutilization of fitness testing and the potential of estimated CRF as 
demonstrated by Stamatakis et al. (18), the purpose of the present analyses is to examine the 
capacity of our new longitudinal CRF algorithms to predict incident CVD and disease-specific 
mortality. This study will add to the previous one (18) by comparing risk predictive capacity 
with measured CRF and by adding non-fatal major CVD events, in a large established database 
with long follow-up. 
 METHODS 
Study population 
The Aerobics Center Longitudinal Study (ACLS) is a prospective observational study of 
adult men and women who underwent preventive medical evaluations at the Cooper Clinic 
(Dallas, TX) (1). Participants were unpaid volunteers, mostly non-Hispanic whites, well 
educated, and worked in executive or professional positions. All participants provided written 
informed consent and the study protocol was approved annually. 
Inclusion criteria for the present analysis were: no existing CVD (myocardial infarction 
[MI] or stroke) or cancer at baseline; achieving 85% or more of the individual’s age-predicted 
maximal heart rate (220 – age) during the treadmill exercise testing; BMI ≥18.5 kg/m2; ≥1 year 
of follow-up; complete data on CRF, mortality outcomes, covariables and all parameters 
included in the CRF algorithms (17). These criteria resulted in 43,356 individuals (21% women) 
aged 20 to 84 years who underwent a baseline examination between 1974 and 2002. 
Baseline examination 
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The clinical examinations were completed after an overnight fast. Height and weight 
were measured on a physician’s scale and stadiometer, and BMI was calculated. Waist 
circumference (WC) was measured level with the umbilicus. Resting systolic and diastolic blood 
pressures were measured with a mercury sphygmomanometer using standard auscultation 
methods (19). Blood chemistries were analyzed with automated bioassays in the Cooper Clinic 
laboratory. Concentrations of total cholesterol and fasting plasma glucose were measured in 
accordance with the standards of the CDC Lipid Standardization Program (20). 
Physical activity 
A formerly validated questionnaire was used to assess self-reported leisure-time physical 
activity (21). A five-level physical activity index was created (17): no regular activity (level 0); 
some regular activity such as bicycling, swimming, racquet sports, and other strenuous sports, 
but not walking or jogging (level 1); walking or jogging < 10 miles per week (level 2); walking 
or jogging 10-20 miles (level 3); and walking or jogging > 20 miles (level 4). Walking and 
jogging were used as the basis for physical activity because they were the most common 
activities in this population. A second physical activity index was defined as inactive (levels 0-2) 
and active (levels 3, 4) to match as closely as possible the consensus recommendation of 150 
minutes per week of aerobic activity (22). 
Measured CRF 
Measured CRF was quantified as the duration of a symptom-limited maximal treadmill 
exercise test using a modified Balke protocol (1,23). Patients were encouraged to give maximal 
effort, and the test endpoint was volitional exhaustion or termination by the physician for 
medical reasons. We calculated METs from the final treadmill speed and grade (24). Exercise 
treadmill duration on this protocol is highly correlated (r ≥ 0.92) with measured peak oxygen 
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uptake (6,7). Participants were classified into lower, middle and upper groups based on age- (20-
39, 40-49, 50-59, ≥ 60 yr) and sex-specific thirds of METs distribution. 
Estimated CRF 
Four different sex-specific algorithms were created to estimate CRF, based on age, BMI 
(or percent body fat), WC, RHR, physical activity index (in two or five levels) and smoking 
status, as previously described and validated (17). For a higher applicability, the present analyses 
focus on those algorithms that include BMI (rather than body fat) and physical activity in two 
levels (rather than five): 
Women 
Estimated CRF (METs) = 14.7873 + (age × 0.1159) – (age2 × 0.0017) – (BMI × 0.1534) – (WC × 
0.0085) – (RHR × 0.0364) + (active × 0.5987) – (smoker × 0.2994)  
Men 
Estimated CRF (METs) = 21.2870 + (age × 0.1654) – (age2 × 0.0023) – (BMI × 0.2318) – (WC × 
0.0337) – (RHR × 0.0390) + (active × 0.6351) – (smoker × 0.4263) 
where active = 1 if the participant was classified as physically active, 0 if inactive; and smoker = 
1 if current smoker, 0 if not. Once the algorithms were implemented, participants were classified 
into lower, middle and upper groups based on age- (20-39, 40-49, 50-59, ≥ 60 yr) and sex-
specific thirds of METs distribution. 
Assessment of outcomes 
Participants were followed from baseline examination until the date of death or 31 
December 2003. Mortality surveillance was based on the national death index (NDI). The 
underlying cause of death was determined from the NDI report or by a nosologist’s review of 
official death certificates. CVD mortality was defined by International Classification of 
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Diseases, Ninth Revision (ICD-9) codes 390 to 449.9 before 1999 and Tenth Revision (ICD-10) 
codes I00 to I78 during 1999–2003 (25). 
Incidence of non-fatal CVD events was ascertained in a subsample of 18,095 individuals 
(20% women) from responses to mail-back health surveys in 1982, 1999, and 2004. The 
aggregate survey response rate across all survey periods in the ACLS is 65% to 75% (26). 
Baseline health histories and clinical measures were similar between responders and non-
responders and between early and late responders (27). 
Non-fatal CVD endpoints were defined as diagnosis by a physician of MI, stroke, or a 
coronary revascularization procedure. In participants reporting multiple events, the first event 
was used for analysis. In a random sample of these endpoints, we applied a standard definition 
for defining and adjudicating MI, revascularization and stroke (28). The percentage of agreement 
between reported events and participants’ medical records was 88, 100, and 89% for MI, 
revascularization, and stroke, respectively (26). 
Statistical Analysis 
Participants’ baseline characteristics were summarized based on sex and estimated CRF 
level, using analysis of the variance (ANOVA) and chi-square tests. We used Cox proportional 
hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) according 
to CRF levels (both measured and estimated). Multivariable analyses included these covariables: 
age (years), examination year, alcohol intake [heavy drinker or not: >14 and >7 drinks / wk for 
males and females, respectively (29)], presence or absence of hypercholesterolemia (total 
cholesterol ≥240 mg/dL or previous physician diagnosis), hypertension (resting blood pressure ≥ 
140/90 mm Hg or previous physician diagnosis), diabetes mellitus (fasting blood glucose ≥126 
mg/dL, previous physician diagnosis or use of insulin), abnormal resting or exercise ECG, and 
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parental history of CVD. Sensitivity analyses compared the performance of the algorithms with 
five and two levels of physical activity, and also excluded intermediate covariables that could be 
on the causal pathway (hypercholesterolemia, hypertension, diabetes). Cumulative hazard plots 
grouped by exposure categories suggested no appreciable violations of the proportional hazards 
assumption. 
To compare the risk predictive capacity of measured CRF and estimated CRF, we 
constructed ROC curves with corresponding areas under the curve (AUC). The AUC (also 
known as c-statistic) is a function of both the sensitivity and specificity of the model across all of 
its values, and it represents the ability of the score to discriminate future cases from non-cases 
(30). Risk predictive capacity of estimated CRF was also compared with its modifiable 
constituent components (BMI, WC, RHR and physical activity). We used existing methods (18) 
to develop a continuous clustered score. After z-score conversion of each variable [z = (value - 
mean) / standard deviation (SD)], the four z-scores were summed and the sum was divided by 4 
to compile a score with units of SD. The continuous variable for physical activity (originally 
active or inactive) was calculated as MET-minutes per week (22). As it is protective, the z-score 
from physical activity was multiplied by -1. Smoking status was not included in this analysis as 
it is defined as a dichotomous variable (current smoker or not). 
Finally, we calculated the net reclassification improvement (NRI) for all-cause mortality 
between estimated CRF and measured CRF. Based on subsequent observed cases, this index 
integrates proportions of appropriate and inappropriate reclassifications between two risk 
prediction models (30). NRI was calculated as (18,31): 
NRI = [P(up|case) – P(down|case) + P(down|non-case) – P(up|non-case)] × 100 
where P is the proportion of participants moving up or down in terms of predicted risk category. 
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The NRI was statistically examined by an asymptotic test (31). 
Data analyses were performed using SPSS version 20.0 (IBM Inc.) and all p values are 2-
sided with an alpha level of 0.05. 
RESULTS 
Descriptive characteristics of the study population are presented in Table 1. Men and 
women with higher levels of estimated CRF had lower BMI, WC, RHR, total cholesterol and 
glucose concentrations (except in women), and systolic and diastolic blood pressures. 
Participants with higher levels of estimated CRF were more likely to be physically active, and 
less likely to be smokers, heavy drinkers (except in women), to have hypercholesterolemia, 
diabetes mellitus, hypertension or abnormal ECG. 
The median (25–75th percentiles) follow-up period for mortality was 14.5 (5.7–20.1) 
years. A total of 1,934 participants died, 627 from CVD. For non-fatal CVD incidence, follow-
up period was 7.7 (2.9–16.5) years and 1,049 cases were registered. Tables 2 and 3 show HRs 
and 95% CIs by CRF levels. In men, both measured CRF and estimated CRF were inversely 
associated with risk of all-cause mortality (HR per 1-MET increase, measured CRF: 0.87, 0.85-
0.89; estimated CRF: 0.85, 0.82-0.88), CVD mortality (measured CRF: 0.83, 0.79-0.86; 
estimated CRF: 0.81, 0.77-0.86), and non-fatal CVD incidence (measured CRF: 0.90, 0.87-0.93; 
estimated CRF: 0.89, 0.85-0.93), after adjustments for potential confounders (table 2). In 
women, both measured CRF and estimated CRF were inversely associated with risk of all-cause 
mortality (measured CRF: 0.91, 0.85-0.99; estimated CRF: 0.87, 0.75-0.99) and non-fatal CVD 
incidence (measured CRF: 0.77, 0.67-0.90; estimated CRF: 0.76, 0.58-0.99) (table 3). Excluding 
hypercholesterolemia, hypertension and diabetes as confounders slightly strengthened some of 
these results (data not shown). 
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Table 4 presents the discrimination statistics of measured CRF and estimated CRF. C-
statistic values (AUC) were slightly higher for measured CRF than estimated CRF. In both cases, 
the discriminative ability was always higher for CVD mortality than for any other outcome. In 
general, c-statistic values were higher in women than men. The lowest c-statistic value was 0.61 
(estimated CRF discriminating non-fatal CVD incidence in men) and the highest was 0.74 
(measured CRF discriminating CVD mortality in women). As it can be observed in Table 5, the 
discriminative ability of estimated CRF was higher to that from any of its modifiable 
components, separately or together, in men and women, and for all outcomes. 
Finally, Table 6 shows the reclassification statistics for all-cause mortality between both 
CRF methods. Compared to estimated CRF, measured CRF reclassified correctly 12.7% of men 
and 20.8% of women who died (i.e. they were reclassified to a higher risk category). The overall 
NRI was 12.3% for men (p<0.05) and 19.8% for women (p<0.001). 
All the analyses (tables 2-6) were repeated using the algorithms with the five-level 
physical activity variable. The results were virtually the same, with a risk predictive capacity and 
discriminative ability very similar to that provided by the two-level physical activity algorithms 
(data not shown). 
DISCUSSION 
The purpose of the present study was to investigate the association of estimated CRF, 
based on longitudinal algorithms, with disease-specific mortality and non-fatal CVD events in 
middle-aged men and women. Previous studies had shown that these (17) and other non-exercise 
equations (10-13,15) estimate CRF with reasonable accuracy at the population level. Now we 
show that estimated CRF, calculated from typically available health indicators, significantly 
predicted future risk of non-fatal CVD as well as all-cause and CVD mortality, after adjustment 
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for standard risk factors. However, these algorithms can still be refined for a better risk 
prediction performance, as measured CRF presented a better discriminative capacity (c-statistic) 
and reclassified correctly a significant proportion of cases (NRI). 
Clinicians have long been aware that patients capable of high levels of physical exertion 
have a better prognosis than those with limited exercise capacity. Data from the ACLS and other 
epidemiologic studies indicate that individuals with low CRF are much more likely to develop 
hypertension (32), diabetes (32,33), and metabolic syndrome (32,34) and to have higher rates of 
death due to CVD (3,35), cancer (36), and all causes (1,3,37). Many experts have recommended 
CRF testing in asymptomatic and symptomatic men and women of all ages (38), and the 
American Heart Association recently highlighted the need for a national CRF registry (39). The 
present algorithms are a practical alternative for an estimate of CRF and a useful tool for 
identifying persons at risk. The potential clinical implications are substantial, as this method 
could be applied to electronic medical record systems and easily determined on patients in 
clinical practice or health maintenance plans. 
The risk reduction per 1-MET increase observed in our study is consistent with previous 
findings using measured CRF (9), and also with the only study so far investigating estimated 
CRF and mortality (18). Similar to our results, these studies have suggested a 10-20% risk 
reduction per 1-MET increase, with the effect being slightly higher for CVD events than for all-
cause mortality (9,18). Between genders, our findings indicate a similar protective trend in men 
and women, although in females there was no association with CVD mortality and the linear 
trend for all-cause mortality did not reach statistical significance. The smaller number of cases in 
women likely decreased the statistical power as suggested in previous ACLS studies (26). In the 
Lipid Research Clinics study (40), CRF predicted CVD mortality risk in women and men, 
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whereas in the Framingham Heart Study, CRF was significantly associated with coronary heart 
disease events in men but not in women (41). The discriminative capacity (c-statistic) of our 
models for CVD mortality (from 0.68 to 0.74) was close to that observed for the Framingham 
risk score and other similar prediction models (0.75-0.80), based on the combination of multiple 
independent risk markers (30). The c-statistic values reported by Stamatakis et al. (18) for CVD 
deaths were also comparable (0.73-75). 
The potential mechanisms for the protective role of estimated CRF could be the same as 
those attributed to measured CRF, achieved in most cases through healthy lifestyle habits: lower 
levels of adiposity, blood pressure and chronic inflammation, higher insulin sensitivity and 
glycemic control, more favorable lipid profile, enhanced endothelial function, improved cardiac 
autonomic regulation, and preserved functional capacity and cognitive ability during aging, 
among others (22). In our study, those participants with higher levels of estimated CRF had 
lower BMI, WC, RHR, cholesterol and glucose concentrations, systolic and diastolic blood 
pressures, and were more likely to be physically active and less likely to be smokers, to have 
hypercholesterolemia, diabetes mellitus or hypertension. 
Notable features make this a robust set of findings: the possibility to compare risk 
predictive capacity between measured CRF and estimated CRF; a large set of major outcomes 
studied (all-cause mortality, CVD mortality and non-fatal CVD incidence); the large sample size 
and long follow-up; and the broad range of potential confounders taken into account. Some 
limitations must also be mentioned and addressed in future research. Measured CRF was not 
directly assessed by gas analysis, but indirectly calculated from treadmill speed and grade. 
Although CPX is considered the gold standard, both assessed and calculated METs from exercise 
tests have shown to be among the strongest predictors of adverse events in a prognostic model 
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(9). The lack of information on diet and medication use/adherence may have introduced some 
residual confounding. The most heavily weighted variable (physical activity) was self-reported, 
although any objective alternative would be less practical. And finally, participants were mostly 
non-Hispanic whites, well-educated and with professional positions, so we do not know how 
well our algorithms would predict health risk in other populations. Cross-validation studies are 
needed to investigate the generalizability of these results by testing the algorithms’ predictive 
capacity in other cohorts. 
In conclusion, our longitudinal algorithms utilize information routinely collected to 
obtain an estimate of CRF that provides a valid indication of health status. Although the method 
can still be refined, estimated CRF significantly predicted risk of non-fatal CVD and all-cause 
and disease-specific mortality. In addition to identifying people at risk, this method can be 
potentially utilized to provide more appropriate exercise recommendations that reflect initial 
CRF levels. 
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Table 1 Baseline Characteristics of Study Participants by Sex and Estimated CRF Level, Aerobics Center Longitudinal Study 1974-
2002 
 Men (n = 34,211)  Women (n = 9,145) 
 Estimated CRF  Estimated CRF 
Characteristic Lower (n = 11,402) 
Middle 
(n = 11,405) 
Upper 
(n = 11,404)  
Lower 
(n = 3,048) 
Middle 
(n = 3,049) 
Upper 
(n = 3,048) 
Age (years) 44.9 (10.0) 44.5 (9.7) 44.0 (9.5) †  44.9 (11.0) 44.5 (10.3) 44.0 (10.7) * 
Body mass index (kg/m2) 30.2 (3.6) 25.9 (1.7) 23.5 (1.7) †  27.1 (4.5) 22.5 (2.0) 20.8 (1.5) † 
Waist circumference (cm) 103.8 (9.4) 92.4 (5.7) 84.9 (6.3) †  82.3 (11.2) 71.4 (7.0) 67.5 (5.3) † 
Resting heart rate (bpm) 66.6 (10.5) 60.4 (8.8) 53.6 (8.4) †  71.0 (10.3) 64.6 (7.8) 56.7 (7.5) † 
Treadmill time (min) 15.1 (3.9) 18.3 (3.9) 22.0 (4.3) †  11.2 (3.6) 13.7 (3.8) 16.5 (4.4) † 
Measured CRF (METs) 10.3 (1.8) 11.8 (1.9) 13.6 (2.3) †  8.5 (1.7) 9.7 (1.8) 10.9 (2.1) † 
Estimated CRF (METs) 10.7 (1.2) 12.4 (0.7) 13.8 (0.8) †  9.0 (0.9) 10.1 (0.5) 10.9 (0.6) † 
Total cholesterol (mg/dL) 215.6 (41.3) 210.0 (43.2) 199.4 (44.5) †  205.7 (39.5) 198.1 (45.5) 192.9 (34.7) † 
Glucose (mg/dL) 104.2 (22.1) 99.4 (15.2) 97.7 (86.9) †  96.5 (15.4) 96.3 (167.5) 91.9 (11.0) 
Blood pressure (mmHg)        
Systolic 125.2 (13.4) 120.3 (12.7) 118.0 (12.9) †  117.7 (14.9) 112.1 (14.1) 109.6 (13.8) † 
Diastolic 84.7 (9.6) 80.8 (9.0) 78.2 (8.8) †  79.2 (9.6) 75.7 (9.1) 73.9 (9.1) † 
Physically Active 645 (5.7) 1,505 (13.2) 5,157 (45.2) †  143 (4.7) 314 (10.3) 1,224 (40.2) † 
Current smokers 2,766 (24.3) 1,983 (17.4) 915 (8.0) †  338 (11.1) 301 (9.9) 148 (4.9) † 
Heavy drinkers 986 (8.6) 981 (8.6) 797 (7.0) †  297 (9.7) 334 (11.0) 361 (11.8) * 
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Values are means (SD). CRF, cardiorespiratory fitness; MET, metabolic equivalent. Analysis of the variance (ANOVA) was used to 
test differences between groups in each sex: * p<0.01; † p<0.001. 
Hypercholesterolemia 4,044 (35.5) 3,238 (28.4) 2,281 (20.0) †  888 (29.1) 616 (20.2) 468 (15.4) † 
Diabetes mellitus 866 (7.6) 404 (3.5) 249 (2.2) †  169 (5.5) 101 (3.3) 85 (2.8) † 
Hypertension 5,168 (45.3) 3,120 (27.4) 2,105 (18.5) †  799 (26.2) 440 (14.4) 342 (11.2) † 
Abnormal ECG 957 (8.4) 804 (7.0) 714 (6.3) †  270 (8.9) 216 (7.1) 158 (5.2) † 
Parental history of CVD 3,152 (27.6) 3,144 (27.6) 3,133 (27.5)  824 (27.0) 842 (27.6) 800 (26.2) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
Table 2 Hazard Ratios for Disease-specific Mortality and Non-fatal CVD According to CRF Levels in 
Men 
 Measured CRF  Estimated CRF 
 
cases / n 
Hazard Ratios (95% CI)  
cases / n 
Hazard Ratios (95% CI) 
 Model 1 * Model 2 †  Model 1 * Model 2 † 
All-cause mortality       
Lower 793/11329 1 (ref) 1 (ref)  642/11402 1 (ref) 1 (ref) 
Middle 524/12164 0.64 (0.57-0.71) 0.68 (0.61-0.76)  557/11405 0.74 (0.66-0.82) 0.79 (0.70-0.88) 
Upper 401/10718 0.49 (0.44-0.55) 0.56 (0.49-0.63)  519/11404 0.59 (0.53-0.67) 0.67 (0.59-0.75) 
P for linear trend < 0.001 < 0.001   < 0.001 < 0.001 
Per 1-MET 0.84 (0.83-0.86) 0.87 (0.85-0.89)   0.82 (0.79-0.84) 0.85 (0.82-0.88) 
CVD mortality       
Lower 304/11329 1 (ref) 1 (ref)  249/11402 1 (ref) 1 (ref) 
Middle 164/12164 0.52 (0.43-0.63) 0.60 (0.49-0.72)  170/11405 0.59 (0.48-0.71) 0.66 (0.54-0.80) 
Upper 109/10718 0.34 (0.27-0.43) 0.45 (0.36-0.57)  158/11404 0.47 (0.38-0.57) 0.59 (0.48-0.73) 
P for linear trend < 0.001 < 0.001   < 0.001 < 0.001 
Per 1-MET 0.78 (0.75-0.81) 0.83 (0.79-0.86)   0.76 (0.72-0.80) 0.81 (0.77-0.86) 
Non-fatal CVD       
Lower 353/4335 1 (ref) 1 (ref)  309/4048 1 (ref) 1 (ref) 
Middle 346/5140 0.72 (0.62-0.83) 0.80 (0.69-0.93)  327/4902 0.76 (0.65-0.89) 0.84 (0.71-0.98) 
Upper 278/4985 0.47 (0.40-0.55) 0.57 (0.48-0.67)  341/5510 0.56 (0.48-0.65) 0.66 (0.56-0.78) 
P for linear trend < 0.001 < 0.001   < 0.001 < 0.001 
Per 1-MET 0.87 (0.84-0.89) 0.90 (0.87-0.93)   0.84 (0.80-0.88) 0.89 (0.85-0.93) 
CI, confidence interval; CRF, cardiorespiratory fitness; CVD, cardiovascular disease; MET, metabolic 
equivalent. * Adjusted for age and examination year. † Adjusted for age, examination year, alcohol intake 
(heavy drinker or not), hypercholesterolemia, hypertension, diabetes, abnormal resting or exercise ECG, 
and parental history of CVD (present or not for each). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
Table 3 Hazard Ratios for Disease-specific Mortality and Non-fatal CVD According to CRF Levels in 
Women 
 Measured CRF  Estimated CRF 
 
cases / n 
Hazard Ratios (95% CI)  
cases / n 
Hazard Ratios (95% CI) 
 Model 1 * Model 2 †  Model 1 * Model 2 † 
All-cause mortality       
Lower 109/3143 1 (ref) 1 (ref)  74/3048 1 (ref) 1 (ref) 
Middle 66/3076 0.92 (0.68-1.25) 0.91 (0.67-1.24)  77/3049 0.83 (0.60-1.14) 0.82 (0.59-1.13) 
Upper 41/2926 0.75 (0.52-1.07) 0.74 (0.52-1.07)  65/3048 0.68 (0.49-0.95) 0.67 (0.48-0.94) 
P for linear trend 0.281 0.275   0.079 0.068 
Per 1-MET 0.92 (0.85-0.99) 0.91 (0.85-0.99)   0.87 (0.75-0.99) 0.87 (0.75-0.99) 
CVD mortality       
Lower 25/3143 1 (ref) 1 (ref)  21/3048 1 (ref) 1 (ref) 
Middle 16/3076 1.05 (0.56-1.97) 1.08 (0.57-2.04)  15/3049 0.63 (0.32-1.22) 0.70 (0.35-1.37) 
Upper 9/2926 0.80 (0.37-1.72) 0.89 (0.41-1.94)  14/3048 0.58 (0.29-1.17) 0.65 (0.32-1.31) 
P for linear trend 0.793 0.905   0.230 0.410 
Per 1-MET 0.92 (0.78-1.09) 0.95 (0.81-1.13)   0.83 (0.63-1.08) 0.84 (0.64-1.12) 
Non-fatal CVD       
Lower 42/1206 1 (ref) 1 (ref)  27/1024 1 (ref) 1 (ref) 
Middle 15/1175 0.35 (0.19-0.63) 0.36 (0.20-0.66)  27/1239 0.64 (0.38-1.11) 0.73 (0.42-1.26) 
Upper 15/1254 0.35 (0.19-0.63) 0.38 (0.21-0.69)  18/1372 0.34 (0.19-0.63) 0.38 (0.20-0.70) 
P for linear trend < 0.001 < 0.001   0.003 0.008 
Per 1-MET 0.75 (0.65-0.87) 0.77 (0.67-0.90)   0.69 (0.54-0.89) 0.76 (0.58-0.99) 
CI, confidence interval; CRF, cardiorespiratory fitness; CVD, cardiovascular disease; MET, metabolic 
equivalent. * Adjusted for age and examination year. † Adjusted for age, examination year, alcohol intake 
(heavy drinker or not), hypercholesterolemia, hypertension, diabetes, abnormal resting or exercise ECG, 
and parental history of CVD (present or not for each). 
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Table 4 Discrimination Statistics of Measured CRF and Estimated CRF for Disease-specific Mortality and Non-fatal CVD 
 Measured CRF  Estimated CRF 
 
All-cause 
mortality 
CVD 
mortality 
Non-fatal 
CVD  
All-cause 
mortality 
CVD 
mortality 
Non-fatal 
CVD 
Men (n = 34,211)        
Cases 1,718 577 977 *  1,718 577 977 * 
Area under the curve 
(95% CI) † 
0.67 
(0.66-0.69) 
0.72 
(0.70-0.74) 
0.62 
(0.60-0.64) 
 
0.63 
(0.61-0.64) 
0.68 
(0.66-0.70) 
0.61 
(0.59-0.62) 
Sensitivity ‡ 0.46 0.53 0.36  0.37 0.43 0.32 
Specificity § 0.68 0.67 0.70  0.67 0.67 0.72 
Women (n = 9,145)        
Cases 216 50 72 *  216 50 72 * 
Area under the curve 
(95% CI) † 
0.70 
(0.66-0.73) 
0.74 
(0.68-0.80) 
0.71 
(0.64-0.77) 
 
0.64 
(0.60-0.68) 
0.73 
(0.66-0.81) 
0.68 
(0.62-0.74) 
Sensitivity ‡ 0.50 0.50 0.58  0.34 0.42 0.38 
Specificity § 0.66 0.66 0.67  0.67 0.67 0.72 
*
 Subsample of 14,460 men and 3,635 women. † Calculated from inverted CRF (as it is protective). ‡ The proportion of cases 
captured by lower CRF group (highest risk). § The proportion of non-cases captured by combined middle and upper CRF groups. 
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Table 5 Area under the curve (AUC) for the modifiable constituent components of the non-exercise CRF algorithms (separately and clustered) 
and for estimated CRF 
 AUC (95% CI) 
 Men (n = 34,211)  Women (n = 9,145) 
 
All-cause 
mortality CVD mortality 
Non-fatal 
CVD *  
All-cause 
mortality CVD mortality 
Non-fatal 
CVD * 
Body mass index 0.49 (0.48-0.51) 0.53 (0.51-0.55) 0.53 (0.51-0.55)  0.50 (0.47-0.54) 0.51 (0.43-0.58) 0.56 (0.50-0.63) 
Waist circumference 0.53 (0.52-0.55) 0.58 (0.55-0.60) 0.56 (0.55-0.58)  0.53 (0.49-0.57) 0.56 (0.49-0.63) 0.59 (0.52-0.65) 
Resting heart rate 0.55 (0.53-0.56) 0.56 (0.54-0.59) 0.52 (0.50-0.54)  0.52 (0.48-0.56) 0.62 (0.55-0.69) 0.56 (0.49-0.62) 
Physical activity † 0.58 (0.57-0.59) 0.57 (0.55-0.60) 0.54 (0.52-0.55)  0.61 (0.58-0.65) 0.61 (0.54-0.69) 0.59 (0.53-0.65) 
Clustered score 0.55 (0.54-0.57) 0.58 (0.56-0.61) 0.56 (0.54-0.57)  0.56 (0.53-0.60) 0.61 (0.54-0.69) 0.62 (0.56-0.68) 
Estimated CRF † 0.63 (0.61-0.64) 0.68 (0.66-0.70) 0.61 (0.59-0.62)  0.64 (0.60-0.68) 0.73 (0.66-0.81) 0.68 (0.62-0.74) 
*
 Subsample of 14,460 men and 3,635 women. † Calculated from inverted physical activity and CRF (as they are protective). 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
26 
Table 6 Reclassification of the Predicted Risk of All-cause Mortality in Men and Women on the 
basis of Estimated CRF vs. Measured CRF 
 Measured CRF Reclassified 
as higher 
risk 
Reclassified 
as lower 
risk 
Net correctly 
reclassified 
(%) Estimated CRF 
Lower 
(highest 
risk) 
Middle Upper 
Men       
Cases (n=1,718)      
Lower (highest risk) 487 132 23 468 250 12.7 
Middle 232 230 95    
Upper 74 162 283    
Non-cases (n=32,493)      
Lower (highest risk) 6,758 3,406 596 6,886 6,760 -0.4 
Middle 2,964 5,126 2,758    
Upper 814 3,108 6,963    
Net Reclassification improvement (NRI) 12.3 % (p<0.05) 
Women       
Cases (n=216)      
Lower (highest risk) 54 16 4 81 36 20.8 
Middle 37 24 16    
Upper 18 26 21    
Non-cases (n=8,929)      
Lower (highest risk) 1,794 874 306 2,099 2,007 -1.0 
Middle 868 1277 827    
Upper 372 859 1,752    
Net Reclassification improvement (NRI) 19.8 % (p<0.001) 
CRF, cardiorespiratory fitness. 
 
 
